CMMB Stock Overview
A clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Chemomab Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.65 |
| 52 Week High | US$2.55 |
| 52 Week Low | US$0.42 |
| Beta | 0.30 |
| 11 Month Change | 14.58% |
| 3 Month Change | 4.43% |
| 1 Year Change | 197.30% |
| 33 Year Change | -81.40% |
| 5 Year Change | n/a |
| Change since IPO | -97.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| CMMB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | 2.5% | 2.2% |
| 1Y | 197.3% | 16.1% | 31.6% |
Return vs Industry: CMMB exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: CMMB exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| CMMB volatility | |
|---|---|
| CMMB Average Weekly Movement | 15.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CMMB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CMMB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Adi George | www.chemomab.com |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. Fundamentals Summary
| CMMB fundamental statistics | |
|---|---|
| Market cap | US$31.11m |
| Earnings (TTM) | -US$14.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs CMMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMMB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.40m |
| Earnings | -US$14.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CMMB perform over the long term?
See historical performance and comparison